BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

Shares of enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) have been assigned a consensus rating of “Buy” from the eleven ...

· Tempus AI, Inc. (NASDAQ: TEM) started 2025 announcing the National Launch of its FDA -approved xT CDx Test, a 648-gene next-generation sequencing test for solid tumor profiling, which includes ...

Cyrus Biotechnology Inc. has selected CYR-212, an engineered next-generation reduced-immunogenicity and half-life extended immunoglobulin G (IgG) protease, as a clinical development candidate for ...

We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this article, we are going to take a ...

A combination therapy of two drugs — a statin and a protein inhibitor — may help suppress the creation and growth of tumors ...

in combination with Bacillus Calmette-Guérin (BCG) to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS), with or without papillary tumors.

ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in the EU and the United Kingdom for Anktiva (nogapendekin alfa inbakicept) in ...

The most common immunotherapy for treating early-stage bladder cancer is the Bacillus Calmette-Guerin (BCG) vaccine treatment. If that fails, the only other alternative is surgery to remove the entire ...

The most common immunotherapy for treating early-stage bladder cancer is the Bacillus Calmette-Guerin (BCG) vaccine treatment. If that fails, the only other alternative is surgery to remove the ...